Home » Stocks » ADXS

Advaxis, Inc. (ADXS)

Stock Price: $0.410 USD -0.002 (-0.49%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $0.413 +0.003 (0.71%) Jul 30, 7:58 PM
Market Cap 61.15M
Revenue (ttm) 2.99M
Net Income (ttm) -21.37M
Shares Out 123.15M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $0.410
Previous Close $0.412
Change ($) -0.002
Change (%) -0.49%
Day's Open 0.413
Day's Range 0.410 - 0.426
Day's Volume 1,949,956
52-Week Range 0.264 - 1.570

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Why These 3 Penny Stocks Are Popular Among Traders Right Now The post Popular Penny Stocks to Buy in 2021? Here's 4 You Should Know About appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other stocks mentioned: BBIG, CETX, TELL
1 week ago - PennyStocks

Reopening penny stocks are showing momentum right now; here's 6 to watch The post Hot Penny Stocks to Buy Now? 6 Reopening Stocks To Watch In July 2021 appeared first on Penny Stocks to Buy, Picks, News...

Other stocks mentioned: ABEV, AHT, ARPO, GSAT, SONM
1 week ago - PennyStocks

NEW YORK, July 16, 2021 /PRNewswire/-- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action ...

2 weeks ago - PRNewsWire

Advaxis Inc (NASDAQ: ADXS) has initiated a Phase 1 study evaluating ADXS-504 in patients with recurrent prostate cancer.  The study, being conducted at Columbia University Irving Medical Center, is the ...

2 weeks ago - Benzinga

Study in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to second indication Study in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to se...

2 weeks ago - GlobeNewsWire

PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today ...

2 weeks ago - GlobeNewsWire

Are you familiar with these hot penny stocks to watch? 7 to keep an eye on right now The post 7 Top Penny Stocks to Watch That You Probably Haven't Heard Of appeared first on Penny Stocks to Buy, Picks,...

Other stocks mentioned: BYFC, CIDM, DPLS
2 weeks ago - PennyStocks

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Advaxis, Inc. (N...

3 weeks ago - Business Wire

NEW YORK, July 6, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Advaxis, Inc. ("Advaxis" or the "Company...

3 weeks ago - PRNewsWire

Biotech penny stocks continue to climb, which companies are on your watchlist? The post Top Biotech Penny Stocks to Buy This Week?

Other stocks mentioned: EYES, RIGL, SNES
3 weeks ago - PennyStocks

Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the bigg...

Other stocks mentioned: ALXO, ODT, PRVB
3 weeks ago - Benzinga

– Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodyspl...

3 weeks ago - GlobeNewsWire

ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA®

1 month ago - GlobeNewsWire

Biotech penny stocks are pushing up; here's 4 for your watchlist The post Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List appeared first on Penny Stocks to Buy, Picks, News and In...

Other stocks mentioned: SESN, TTOO, TYME
2 months ago - PennyStocks

Looking for top penny stocks to buy under $2? Check these 3 out for some watchlist inspiration The post 3 Penny Stocks To Watch Under $2 Making Big Moves Today appeared first on Penny Stocks to Buy, Pic...

Other stocks mentioned: NGD, TYME
2 months ago - PennyStocks

Advaxis Inc (NASDAQ: ADXS) announced updated data from its Phase 1/2 study evaluating ADXS-503 in combination with Merck & Co Inc's Keytruda (pembrolizumab) in patients with metastatic non-small-cell lu...

2 months ago - Benzinga

Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab

2 months ago - GlobeNewsWire

Best biotech penny stocks to buy during the crypto crash? Check these 3 out The post Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25% appeared first on Penny Stocks to Buy, Picks, New...

Other stocks mentioned: ACST, AGEN
2 months ago - PennyStocks

PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today...

3 months ago - GlobeNewsWire

Non-dilutive capital will support advancement of ADXS-HOT neoantigen program Non-dilutive capital will support advancement of ADXS-HOT neoantigen program

3 months ago - GlobeNewsWire

Non-dilutive capital to support advancement of ADXS-HOT neoantigen program Non-dilutive capital to support advancement of ADXS-HOT neoantigen program

3 months ago - GlobeNewsWire

Advaxis, Inc. (NASDAQ: ADXS), CEO Ken Berlin presented at the Benzinga Biotech Small-Cap Conference on March 24, 2021. Advaxis, Inc., a clinical-stage biotechnology company focused on the development an...

3 months ago - Benzinga

PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...

3 months ago - GlobeNewsWire

Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade

3 months ago - GlobeNewsWire

PRINCETON, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and P...

4 months ago - GlobeNewsWire

Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors

6 months ago - GlobeNewsWire

Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program

6 months ago - GlobeNewsWire

PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today ...

7 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - December 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Advaxis, Inc. (NASDAQ: ADXS) concerning possible breaches of fiduciary duty. To...

7 months ago - Newsfile Corp

PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy ...

8 months ago - GlobeNewsWire

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their ...

8 months ago - Insider Monkey

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluria type 1 t...

Other stocks mentioned: ALNY, ARWR
8 months ago - Benzinga

PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy ...

8 months ago - GlobeNewsWire

PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy ...

8 months ago - GlobeNewsWire

Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA ®

8 months ago - GlobeNewsWire

PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis , Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today...

9 months ago - GlobeNewsWire

PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, tod...

10 months ago - GlobeNewsWire

Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND

10 months ago - GlobeNewsWire

Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors

10 months ago - GlobeNewsWire

PRINCETON, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products toda...

10 months ago - GlobeNewsWire

PRINCETON, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, toda...

11 months ago - GlobeNewsWire

PRINCETON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today...

11 months ago - GlobeNewsWire

PRINCETON, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, toda...

1 year ago - GlobeNewsWire

Advaxis, Inc. (ADXS) CEO Ken Berlin on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with KEYTRUDA®

1 year ago - GlobeNewsWire

Sustained clinical benefit seen in patients treated with ADXS-503 in combination with KEYTRUDA® after 16 weeks, including a partial response and stable disease in patients who had most recently progress...

1 year ago - GlobeNewsWire

Advaxis Is One Biotech That Should Be On Your Radar; Targeting Large NSCLC And Prostate Cancer Drug Markets

1 year ago - Seeking Alpha

First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA®

1 year ago - GlobeNewsWire

PRINCETON, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherap...

1 year ago - GlobeNewsWire

Advaxis, Inc. (ADXS) CEO Kenneth Berlin on Q2 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About ADXS

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunothe... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
Kenneth Berlin
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
ADXS
Full Company Profile

Financial Performance

In 2020, Advaxis's revenue was $253,000, a decrease of -98.79% compared to the previous year's $20.88 million. Losses were -$26.47 million, 59.3% more than in 2019.

Financial Statements